BiotechTube

Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)

Phase 3Recruiting
0 views this week 0 watching⚡ Active🧠Featured in Neuroscience Pipeline Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Progressive Multiple Sclerosis (SPMS)

Conditions

Secondary Progressive Multiple Sclerosis (SPMS)

Trial Timeline

Nov 11, 2025 → Jan 2, 2034

NCT ID
NCT07225504

About Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)

Remibrutinib (blinded) + Placebo + Remibrutinib (Open label) is a phase 3 stage product being developed by Novartis for Secondary Progressive Multiple Sclerosis (SPMS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07225504. Target conditions include Secondary Progressive Multiple Sclerosis (SPMS).

What happened to similar drugs?

6 of 20 similar drugs in Secondary Progressive Multiple Sclerosis (SPMS) were approved

Approved (6) Terminated (0) Active (14)
🔄KHK7580Kyowa KirinPhase 3
🔄KHK7580Kyowa KirinPhase 3
✅Cinacalcet HClKyowa KirinApproved
🔄KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
🔄paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07225504Phase 3Recruiting

Competing Products

20 competing products in Secondary Progressive Multiple Sclerosis (SPMS)

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
35
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Birabresib Dose 20 mgMerckPhase 1
21
RanibizumabNovartisApproved
43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
40